Nature Clinical Practice Oncology

Articles Available on Medscape

• Intermittent Androgen Blockade Should be Regarded as Standard Therapy in Prostate Cancer
  Over 80 percent of men with advanced prostate cancer respond to standard treatment with continuous androgen deprivation therapy. Why should it be the standard?

  October 17, 2008

• The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co-Expression of HER2
  What progress has been made in understanding resistance to endocrine therapy? Insights into the management of patients with HER2-positive advanced breast cancer are presented.

  September 30, 2008

• Chemotherapy for Muscle-invasive Bladder Cancer Treated with Definitive Radiotherapy: Persisting Uncertainties
  Multi-modal treatment for invasive bladder cancer has been shown to be effective, however, definitive evidence is still lacking. Learn more about combination therapies and how they affect survival.

  August 21, 2008

• Lumpectomy and Partial Breast Irradiation for Early-stage Breast Cancer Following Mantle Irradiation for Hodgkin's Lymphoma
  Irradiation for Hodgkin's lymphoma increases the risk of breast cancer. A case report of a 57-year-old woman details this latent disease trajectory.

  August 12, 2008

• Rapamycin Treatment for a Child With Germline PTEN Mutation
  Proteus syndrome is a rare hamartoma syndrome characterized by germline PTEN mutations. How effective is oral rapamycin therapy for its treatment?

  June 11, 2008

• Should Adjuvant Imatinib Be Used as Primary Treatment for Gastrointestinal Stromal Tumors?
  Gastrointestinal stromal tumor metastases can be controlled by imatinib but not by systemic chemotherapy/radiotherapy. Can imatinib be used as adjuvant therapy in GIST patients at risk for metastases?

  May 20, 2008

• Metastasis: A Therapeutic Target for Cancer
  Metastasis remains the major driver of mortality in patients with cancer. Learn why the time is ripe for metastasis and metastatic colonization to enter mainstream clinical development and testing.

  April 24, 2008

• The Main Site of Origin for Malignancies Detected During Risk-Reducing Surgery for Ovarian Cancer
  BRCA-positive women may opt to undergo prophylactic surgery to reduce the risk of ovarian cancer. What are the location and frequency of malignancies that are identified at the time of the surgery?

  April 16, 2008

• Drug Insight: Gastrointestinal Stromal Tumors (GIST)--The Solid Tumor Model for Cancer-Specific Treatment
  Gastrointestinal stromal tumors are among the first solid tumors for which cancer-(cell-)specific therapy became available. What is its pathogenesis, therapy strategies and drug resistance mechanisms?

  April 09, 2008

• Prognostic False-positivity of the Sentinel Node in Melanoma
  Will all positive sentinel lymph nodes progress to palpable nodal recurrence if not removed?

  January 11, 2008

• Prophylactic Surgery Prevents Endometrial and Ovarian Cancer in Lynch Syndrome
  What's the rationale for prophylactic gyn surgery in women with mismatch-repair mutation causal to Lynch syndrome post-childbearing with testing and surveillance unless and until such surgery is done?

  December 04, 2007

• Stereotactic Radiotherapy for Stage I Non-Small-Cell Lung Cancer--The Triumph of Technology Over Biology?
  Should stage I non-small-cell lung cancer patients who are unsuitable for surgery receive hypofractionated stereotactic radiotherapy? How safe is this form of radiation treatment?

  November 08, 2007

• Molecular Imaging can Accelerate Anti-Angiogenic Drug Development and Testing
  Angiogenesis is regulated by numerous molecular pathways that could serve as targets for molecular imaging. What is the role of molecular imaging in anti-angiogenic drug development?

  October 25, 2007

• Is Single-Agent Temozolomide the Treatment of Choice for Recurrent Primary Central Nervous System Lymphoma?
  Recurrent primary central nervous system lymphoma (PCNSL) patients have limited treatment options. How does temozolomide fare as single-agent therapy in patients with relapsed or refractory PCNSL?

  September 11, 2007

• Surgery Insight: Surgical Management of Pancreatic Cancer
  Pancreatic ductal adenocarcinoma's most important treatment modality is surgery, but it is a complex procedure. What technical improvements have made pancreatic surgery safer? What are the challenges?

  September 07, 2007

• Angiogenesis Inhibition: The Next Frontier in Multimodal Therapy for Glioblastoma Multiforme
  Might an antiangiogenic agent impact glioblastoma multiforme tumor vasculature? How will its actions affect efficacy of cytotoxic therapy?

  August 14, 2007

• Management of Nonmelanoma Skin Cancer in 2007
  Nonmelanoma skin cancer has an increasing number of treatment modalities. This review presents an overview of management options ranging from the newer, noninvasive treatments to surgical approaches.

  August 07, 2007

• Strategies for the Management of Hepatocellular Carcinoma
  Regarding hepatocellular carcinoma, when should liver resection, nonsurgical treatment, and management before liver transplantation be considered? What are the applications of nonsystemic therapies?

  July 24, 2007

• Is Stereotactic Radiosurgery the Best Treatment Option for Patients with Spinal Metastases?
  Single-fraction stereotactic radiosurgery is an effective treatment for patients with brain tumors and brain metastases. How about for patients with spinal metastases?

  July 19, 2007

• Heart Failure in Childhood Cancer Survivors
  The number of adult childhood cancer survivors has increased, in part because of the introduction of anthracyclines. However, survivors are at risk for A-CHF from this therapy’s cardiotoxic effects.

  July 03, 2007